Planned Conversion From TAC to SRL-based Regimen in de Novo Kidney Transplant Recipients
Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
Background Early conversion from calcineurin inhibitor to mammalian target of rapamycin
inhibitor is one of the immunosuppressive strategies that have been investigated to mitigate
long-term CNi associated adverse events. This study aims to evaluate the conversion from
tacrolimus to sirolimus in de novo kidney transplant recipients.
This multicenter, open-label study, planned to enroll 297 patients initially treated with
tacrolimus, enteric-coated mycophenolate sodium (1440 mg/day, orally) and prednisone. The
primary objective is to show superior glomerular filtration rate in the SRL group at 24
months after transplantation.